One Federal St.\\Boston, MA 02110-1726\\United States
Julio Vega represents public and private companies in a broad range of industries, including biotechnology, medical devices, nanotechnology, advanced materials, software, networking, e-commerce, and fintech. Julio has experience counseling clients on venture capital and other private equity financing transactions, public offerings, mergers and acquisitions, joint ventures, strategic alliances, licensing, and corporate partnering transactions. He regularly counsels clients on general corporate, employee compensation, and corporate governance matters. Julio is also very active in the representation of startup and emerging growth companies in the life sciences and technology industries.
Julio also has experience advising on international transactions and is fluent in Spanish.
Prior to joining Morgan Lewis, Julio was a partner in the emerging company, venture capital, mergers and acquisitions and securities practice of another international firm.
selected representations
M&A Transactions
Represented Rhythm Health, Inc. in connection with its grant to Actavis of an option to acquire Rhythm Health
Represented Sideris Pharmaceuticals in connection with its grant to Novartis of an option to acquire Sideris
Represented Proteon Therapeutics in connection with its grant to Novartis of an option to acquire Proteon
Represented Bioassets Development Corp. in connection with its sale to Cephalon
Represented VisEn Medical in connection with its acquisition by PerkinElmer.
Represented Novazyme Pharmaceuticals in connection with its acquisition by Genzyme.
Represented Cubist Pharmaceuticals in connection with its acquisition of Calixa.
Represented LeukoSite in connection with its acquisition by Millennium Pharmaceuticals.
Represented Acme Packet in connection with its acquisitions of Covergence.
Represented Acme Packet in connection with its acquisitions of Newfound Communications
Represented Acme Packet in connection with its acquisitions of Iptego GmbH.
Represented Acme Packet in connection with its sale to Oracle
Represented E Ink in connection with its sale to PrimeView International.
Represented Voice Signal Technologies in connection with its acquisition by Nuance Communications
Licensing and Collaboration Transactions
Represented Biogen Idec in connection with Option and License Agreement with AVEO Pharmaceuticals.
Represented Radius Health Inc. in connection with License Agreement with Ipsen S.A..
Represented BioAssets Development Corporation in connection with Collaboration and License Agreement between BioAssets and Biogen Idec (via Eidetica Biopharma GmbH).
Represented Serono S.A. in connection with Research Collaboration and License Agreement with Paratek Pharmaceuticals
Represented Serono S.A. in connection with Research Collaboration and License Agreement with Ambrx Pharmaceuticals
Represented Fovea Pharmaceuticals, S.A. in connection with License Agreement with Dyax Corp.
Represented Proteostasis Therapeutics in connection with Strategic Alliance Agreement with Elan.
Represented Rhythm Pharmaceuticals in connection with in-license from Ipsen S.A.
Represented TolerRx in connection with License Agreement with GlaxoSmithKline plc.
IPOs
Initial Public Offering of Proteon Therapeutics (issuer’s counsel)
Initial Public Offering of Radius Health (underwriter’s counsel)
Initial Public Offering of Rhythm Pharmaceuticals, Inc. (issuer’s counsel)
Initial Public Offering of Amicus Therapeutics, Inc. (issuer’s counsel)
Initial Public Offering of Acme Packet, Inc. (issuer’s counsel)
Initial Public Offering of Aspen Technology, Inc. (issuer’s counsel)
Initial Public Offering of Cubist Pharmaceuticals, Inc. (issuer’s counsel)
Initial Public Offering of Leukosite, Inc. (issuer’s counsel
Initial Public Offering of Acme Packet, Inc. (issuer’s counsel)
